Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

21 citing papers in PubMed, 37 citations in OpenAlex.

1. Safety and immunogenicity of a SARS-CoV-2 Gamma variant RBD-based protein adjuvanted vaccine used as booster in healthy adults.Nature communications · 2023
   Trial
2. Mechanisms Underlying the Induction of Immunological Imprinting by RNA Viruses and Intervention Strategies.Viruses · 2026
   Review
3. Developing the next-generation of adenoviral vector vaccines.Human vaccines & immunotherapeutics · 2025
   Review
4. Vaccination Strategies: Mixing Paths Versus Matching Tracks.Vaccines · 2025
   Review
5. A Potential Association between Abdominal Obesity and the Efficacy of Humoral Immunity Induced by COVID-19 and by the AZD1222, Convidecia, BNT162b2, Sputnik V, and CoronaVac Vaccines.Vaccines · 2024
   Article
6. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina.Frontiers in immunology · 2024
   Observational
7. Safety and immunogenicity of different booster vaccination schemes for COVID-19 used in El Salvador.Clinical and experimental vaccine research · 2024
   Article
8. Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023
   Review
9. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study.Heliyon · 2023
   Article
10. A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers.Vaccines · 2023
    Article
11. Soluble SARS-CoV-2 RBD and human ACE2 peptidase domain produced in Drosophila S2 cells show functions evoking virus-cell interface.Protein science : a publication of the Protein Society · 2023
    Article
12. Considerations for vaccinating children against COVID-19.BMJ paediatrics open · 2023
    Review
13. High-dimensional analysis of 16 SARS-CoV-2 vaccine combinations reveals lymphocyte signatures correlating with immunogenicity.Nature immunology · 2023
    Article
14. Evaluation of the Diagnostic Performance of Two Automated SARS-CoV-2 Neutralization Immunoassays following Two Doses of mRNA, Adenoviral Vector, and Inactivated Whole-Virus Vaccinations in COVID-19 Naïve Subjects.Microorganisms · 2023
    Article
15. Comparison of Immunogenicity and Reactogenicity of Five Primary Series of COVID-19 Vaccine Regimens against Circulating SARS-CoV-2 Variants of Concern among Healthy Thai Populations.Vaccines · 2023
    Article
16. Evaluation of the Efficacy of BBIBP-CorV Inactivated Vaccine Combined with BNT62b2 mRNA Booster Vaccine.Diagnostics (Basel, Switzerland) · 2023
    Article
17. Heterologous booster with a novel formulation containing glycosylated trimeric S protein is effective against Omicron.Frontiers in immunology · 2023
    Article
18. Immunogenicity and Durability of Antibody Responses to Homologous and Heterologous Vaccinations with BNT162b2 and ChAdOx1 Vaccines for COVID-19.Vaccines · 2022
    Article
19. SARS-CoV-2-Specific IgG and IgA response in maternal blood and breastmilk of vaccinated naïve and convalescent lactating participants.Frontiers in immunology · 2022
    Article
20. Is heterologous prime-boost COVID-19 vaccination a concern or an opportunity for Ethiopia?Frontiers in public health · 2022
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

57 authors at 9 institutions in 1 country.

Funding

Abstract

Indexed as